Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Emeritus Professor Angela Vincent received the Research Recognition Award, clinical science, at the annual meeting of the American Epilepsy Society.

Angela Vincent at a lectern

The AES is a medical and scientific society whose members are dedicated to advancing research and education for preventing, treating and curing epilepsy. The AES  Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. The awards recognise professional excellence reflected in a distinguished history of research of important promise for the improved understanding and treatment of epilepsy. These awards include a $10,000 honorarium.The clinical science award was shared by Angela Vincent and J Dalmau.

As an honorary consultant in immunology, Angela Vincent established and directed the Oxford Neuroimmunology Service from 1992-2016. She was president of the International Society of Neuroimmunology (2001-2004), Head of the Department of Clinical Neurology (2005- 2008), and associate editor of Oxford Academic's Brain (2004-2013).

Although she is not a neurologist, Professor Vincent received the 2009 Association of British Neurologists medal and the 2017 World Federation for Neurology (WFN) Medal for scientific contributions to neurology. In 2018, she received the Klaus Joachim Zülch Prize with two other doctors. She was elected Fellow of the Academy of Medical Sciences in 2002 and Fellow of the Royal Society of London in 2011.

Angela's interests include clinical and serological studies on patients with neuromuscular junction disorders and acquired disorders of the central nervous system associated with antibodies to receptors, ion channels and associated proteins, which causes a wide range of issues including amnesia, seizures, psychiatric and movement disorders. She also pioneered the role of maternal antibodies in causing neuronal pathology that could influence susceptibility to developmental and other neurological diseases. She received her M.B.B.S. and M.Sc. in biochemistry from University College of London.

Similar stories

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Clinical Neurology Research

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Low-cost ventilator wins at E&T Innovation Awards

Anaesthetics Award Coronavirus

The OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.